{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:51:18Z","timestamp":1762980678389,"version":"3.40.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijrobp.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:39:26Z","timestamp":1555414766000},"page":"1066-1073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study"],"prefix":"10.1016","volume":"104","author":[{"given":"Yasir","family":"Alayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-1781","authenticated-orcid":false,"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motasem","family":"Al-Hanaqta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananth","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Deabreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darby","family":"Erler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.04.006_bib1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40258-014-0106-9","article-title":"Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013","volume":"12","author":"Amin","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clon.2015.01.011","article-title":"Stereotactic body radiotherapy for prostate cancer","volume":"27","author":"Henderson","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib7","first-page":"e1668","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: A ten-year analysis","volume":"9","author":"Katz","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib8","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2015.02.023","article-title":"High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success","volume":"115","author":"Helou","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2010.02.196","article-title":"Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT","volume":"9","author":"Deutsch","year":"2010","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijrobp.2008.05.003","article-title":"An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome","volume":"73","author":"Bachand","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1200\/JCO.2016.72.0466","article-title":"Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update","volume":"35","author":"Chin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-1","article-title":"Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: A six year study","volume":"9","author":"Katz","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1111\/ajco.12455","article-title":"Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer","volume":"13","author":"Kim","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13014-016-0585-y","article-title":"Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer","volume":"11","author":"Anwar","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2014.00278","article-title":"The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer","volume":"4","author":"Lin","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijrobp.2004.09.051","article-title":"Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer","volume":"62","author":"Cheung","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0360-3016(01)02805-X","article-title":"Inclusion of geometric uncertainties in treatment plan evaluation","volume":"52","author":"van Herk","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.04.006_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2013.10.010","article-title":"Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival","volume":"88","author":"Lo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619306248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619306248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T21:45:21Z","timestamp":1563486321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619306248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0360301619306248"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.006","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}